Properties
What is it?
CEFTRIAXONE NORMON Powder for solution for injection IM 1000mg vial + solvent 3.5ml Composition: The active substance is ceftriaxone (as ceftriaxone sodium). Each vial contains 1,000 mg of ceftriaxone (as ceftriaxone sodium). The ampoule with solvent contains 35 mg of lidocaine hydrochloride monohydrate. After dilution in 3.5 ml of lidocaine hydrochloride monohydrate in the solvent ampoule, the concentration of the solution is 285.71 mg of ceftriaxone (as ceftriaxone sodium) per 1 ml. Other ingredients are (excipients): Solvent ampoule: water for injections. Indications: Bacterial meningitis; Intra-abdominal infections (such as peritonitis and biliary tract infections); Bone and joint infections, complicated skin and soft tissue infections; Complicated urinary tract infections, including pyelonephritis (kidney infection); Respiratory tract infections; Genital infections (including gonococcal infections); Stages II and III of Lyme disease (tick-borne illness). Ceftriaxone is also indicated for the prevention of infections before or after surgery. Dosage: Adults, children over 12 years of age with a body weight ≥50 kg: 1-2 g of ceftriaxone every 24 hours, i.e., 1-2 g/day; in severe cases, the dose may be increased to 4 g/day. Gonococcal disease (uncomplicated genital infection): a single intramuscular dose of 250 mg is recommended. Stages II and III of Lyme disease: the recommended dose is 50 mg/kg body weight up to a maximum dose of 2 g once daily for 14 days. Prevention of infections before and after surgery: 1-2 g of ceftriaxone 30-90 minutes before surgery. Patients with impaired renal or hepatic function: In patients with altered renal function, no dose reduction of Ceftriaxone Normon is necessary if hepatic function is normal. If creatinine clearance is <10 ml/min, the dose of ceftriaxone should not exceed 2 g per day. Patients on dialysis: No additional extra dose is required after dialysis; however, serum concentration monitoring is necessary to determine the need for dose adjustment, as the elimination rate may be reduced in such patients. Elderly patients: No change in the recommended doses for adults is necessary in elderly patients. Children under 12 years of age: Neonates (up to 14 days): 20-50 mg/kg body weight, administered as a single dose in both term and preterm neonates. The dose should not exceed 50 mg/kg body weight. Neonatal infants (15-28 days), infants (28 days to 23 months) and children (2-12 years): a single daily dose of 20-80 mg/kg body weight. Bacterial meningitis in neonatal infants (15-28 days), infants (28 days to 23 months) and children (2-12 years): treatment is initiated with a dose of 100 mg/kg (dose should not exceed 4 g) once daily. As soon as the causative agent of the infection and its sensitivity are identified, the dose should be adjusted accordingly. Method of administration: Ceftriaxone is administered intramuscularly (into the muscle). For intramuscular injection, the contents of the vial should be dissolved in 3.5 ml of solvent, which is contained in the accompanying ampoule. This medication should be administered by a medical professional. If the patient is unsure, consult your doctor or pharmacist. Based on the disease, age, weight, and response to treatment with the medication, the doctor will determine the appropriate dose and duration of treatment for the patient. Do not arbitrarily change the dose. If the patient believes that the effect of the medication is too strong or too weak, consult your doctor or pharmacist. Medication should be continued for at least 2-3 days after recovery or for a few days after surgery for infection prevention. The medication should always be used in accordance with the instructions in the leaflet or exactly as prescribed by your doctor or pharmacist. If the patient is unsure, consult your doctor or pharmacist. Storage: Keep out of reach of children. Store below 25°C. Store in the original packaging to protect from light.
